Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Thoracic Cancer|October 4, 2022
Is using a consolidation tumor ratio 0.5 as criterion feasible in daily practice? Evaluation of interobserver measurement variability of consolidation tumor ratio of lung cancer less than 3 cm in sizeSachie Koike, Kimihiro Shimizu, Shogo Ide, et al.
Clinical Lung Cancer|January 13, 2023
Epidemiological and Therapeutic Analyses in Lung Cancer Patients Over 80 Years Old in the Hokushin Region: A Retrospective Hospital Administrative Database StudyTomonobu Koizumi, Yoshikazu Nishino, Tomoya Takiguchi, et al.
Respiratory Investigation|January 21, 2024
EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational studyTaisuke Araki, Shintaro Kanda, Miho Obara, et al.
Thoracic Cancer|May 26, 2022
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapyTaisuke Araki, Kazunari Tateishi, Masamichi Komatsu, et al.
Respiratory Investigation|July 27, 2025
Real-world data after introduction of chemoimmunotherapy in patients with extensive-disease small cell lung cancer: A multicenter retrospective studyTaro Hirabayashi, Kei Sonehara, Toshiharu Tsutsui, et al.
Cancer Medicine|May 22, 2026
Real-World Data of Second-Line Amrubicin Monotherapy in Patients With Extensive-Stage Small Cell Lung Cancer Who Received First-Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective StudyKei Sonehara, Toshiharu Tsutsui, Shuhei Nozawa, et al.
Translational Lung Cancer Research|July 10, 2023
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)Taisuke Araki, Shintaro Kanda, Masamichi Komatsu, et al.
Pageof 4